Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16416413 | 0.81 | NR4A2 (0.40) | BAZ2BBAZ2AALDH1A1NR4A2CYP1A2 | |
| SCHEMBL21408349 | 0.80 | BAZ2B (0.40) | BAZ2BBAZ2AALDH1A1NR4A2KMT2A | |
| SCHEMBL16416800 | 0.77 | BAZ2B (0.46) | BAZ2BBAZ2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL16417232 | 0.75 | NR4A2 (0.35) | BAZ2BBAZ2ANR4A2CYP1A2CYP2C19 | |
| SCHEMBL17838308 | 0.74 | BAZ2B (0.43) | BAZ2BBAZ2AALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL21413174 | 0.74 | BAZ2B (0.49) | BAZ2BBAZ2AALDH1A1CYP1A2KDM4E | |
| SCHEMBL29712820 | 0.72 | BAZ2B (0.40) | BAZ2BBAZ2AALDH1A1MAPTCNR1 | |
| SCHEMBL17838262 | 0.70 | ALDH1A1 (0.36) | ALDH1A1NR4A2CYP1A2CYP2C19KDM4E | |
| SCHEMBL16417169 | 0.70 | ALDH1A1 (0.36) | ALDH1A1NR4A2CYP1A2CYP2C19KDM4E | |
| SCHEMBL29712831 | 0.70 | MAPT (0.36) | ALDH1A1NR4A2MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111601788-B | Capsid protein assembly inhibitor, pharmaceutical composition and use thereof | 正大天晴药业集团股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-108047115-B | Glyoxylamide-substituted pyrrole amide derivatives and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-111601788-A | Capsid protein assembly inhibitor, pharmaceutical composition and use thereof | 正大天晴药业集团股份有限公司 | 2020-08-28 | — | — | CN | disclosed |
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-22 | — | — | US | disclosed |
| EP-3357906-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2018-08-08 | — | — | EP | disclosed |
| EP-3024819-B1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-21 | — | — | EP | disclosed |
| US-20160176817-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | GRHPR, AGXT, GLS2 | BAZ2B 159/4885BAZ2A 212/4885GPR35 1713/4885 |
| US-20160176817-A1 | GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | GRHPR, AGXT, GLS2 | BAZ2B 159/4885BAZ2A 212/4885GPR35 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.